Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 43 | 2020 | 1428 | 4.740 |
Why?
|
Orbit | 10 | 2023 | 210 | 3.860 |
Why?
|
Eyelids | 16 | 2023 | 170 | 3.340 |
Why?
|
Hypoglycemic Agents | 21 | 2020 | 609 | 3.320 |
Why?
|
Orbital Diseases | 6 | 2022 | 116 | 2.710 |
Why?
|
Lacrimal Apparatus Diseases | 9 | 2023 | 142 | 2.710 |
Why?
|
Insulin Resistance | 19 | 2020 | 744 | 2.490 |
Why?
|
Thiazolidinediones | 11 | 2015 | 152 | 2.400 |
Why?
|
Conjunctival Neoplasms | 4 | 2022 | 124 | 2.170 |
Why?
|
Oculomotor Muscles | 6 | 2019 | 131 | 2.150 |
Why?
|
Orbital Neoplasms | 9 | 2024 | 230 | 2.090 |
Why?
|
Blood Glucose | 28 | 2021 | 1269 | 2.040 |
Why?
|
Fatty Acids, Nonesterified | 19 | 2012 | 160 | 2.000 |
Why?
|
Eyelid Neoplasms | 10 | 2022 | 192 | 1.940 |
Why?
|
Eye Foreign Bodies | 5 | 2020 | 15 | 1.880 |
Why?
|
Sebaceous Gland Neoplasms | 8 | 2022 | 100 | 1.720 |
Why?
|
Blepharoptosis | 6 | 2018 | 70 | 1.640 |
Why?
|
Exophthalmos | 5 | 2019 | 46 | 1.620 |
Why?
|
Eyelid Diseases | 5 | 2022 | 75 | 1.590 |
Why?
|
Dermoid Cyst | 2 | 2023 | 38 | 1.530 |
Why?
|
Eye Injuries | 3 | 2019 | 54 | 1.400 |
Why?
|
Retinoblastoma | 6 | 2023 | 195 | 1.390 |
Why?
|
Hemangioma, Capillary | 5 | 2021 | 29 | 1.390 |
Why?
|
Adiponectin | 12 | 2017 | 167 | 1.360 |
Why?
|
Dacryocystorhinostomy | 5 | 2023 | 40 | 1.360 |
Why?
|
Lacrimal Apparatus | 5 | 2023 | 189 | 1.330 |
Why?
|
Retinal Neoplasms | 5 | 2023 | 141 | 1.280 |
Why?
|
Cysticercosis | 5 | 2021 | 32 | 1.280 |
Why?
|
Venoms | 5 | 2012 | 24 | 1.250 |
Why?
|
Orbital Pseudotumor | 2 | 2019 | 13 | 1.220 |
Why?
|
Insulin | 20 | 2014 | 1474 | 1.200 |
Why?
|
Adipose Tissue | 4 | 2023 | 775 | 1.170 |
Why?
|
Orbit Evisceration | 4 | 2024 | 47 | 1.150 |
Why?
|
Jaw Abnormalities | 2 | 2018 | 4 | 1.140 |
Why?
|
Hematoma | 2 | 2018 | 167 | 1.080 |
Why?
|
Conjunctiva | 5 | 2020 | 250 | 1.070 |
Why?
|
Liver | 9 | 2018 | 2990 | 1.060 |
Why?
|
Lacrimal Duct Obstruction | 4 | 2023 | 52 | 1.050 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 5 | 2019 | 21 | 1.000 |
Why?
|
Muscle, Skeletal | 9 | 2014 | 1328 | 1.000 |
Why?
|
Glucagon-Like Peptide 1 | 4 | 2013 | 71 | 0.960 |
Why?
|
Eye Abnormalities | 2 | 2022 | 113 | 0.960 |
Why?
|
Autoimmune Diseases | 2 | 2019 | 418 | 0.930 |
Why?
|
Diabetic Angiopathies | 3 | 2016 | 83 | 0.910 |
Why?
|
Peptides | 6 | 2016 | 1504 | 0.900 |
Why?
|
Optic Nerve Neoplasms | 1 | 2023 | 37 | 0.890 |
Why?
|
Humans | 139 | 2024 | 270843 | 0.880 |
Why?
|
Ectropion | 1 | 2022 | 12 | 0.860 |
Why?
|
Microscopy, Acoustic | 3 | 2022 | 26 | 0.850 |
Why?
|
Fraser Syndrome | 1 | 2022 | 1 | 0.850 |
Why?
|
Facial Neoplasms | 1 | 2023 | 80 | 0.840 |
Why?
|
Syndactyly | 1 | 2022 | 26 | 0.830 |
Why?
|
Fistula | 1 | 2023 | 79 | 0.820 |
Why?
|
Microphthalmos | 1 | 2022 | 54 | 0.820 |
Why?
|
Nervous System Diseases | 2 | 2018 | 525 | 0.800 |
Why?
|
Timolol | 2 | 2021 | 9 | 0.800 |
Why?
|
Male | 97 | 2024 | 127630 | 0.800 |
Why?
|
Eye Hemorrhage | 2 | 2020 | 3 | 0.770 |
Why?
|
PPAR gamma | 6 | 2020 | 231 | 0.770 |
Why?
|
Exoribonucleases | 1 | 2021 | 42 | 0.760 |
Why?
|
Eye Neoplasms | 6 | 2021 | 254 | 0.740 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2020 | 21 | 0.740 |
Why?
|
Wood | 1 | 2020 | 18 | 0.740 |
Why?
|
Fibrin Tissue Adhesive | 1 | 2020 | 26 | 0.740 |
Why?
|
Optic Nerve Injuries | 1 | 2020 | 14 | 0.740 |
Why?
|
Lipid Metabolism | 5 | 2010 | 487 | 0.740 |
Why?
|
Blepharophimosis | 2 | 2018 | 19 | 0.730 |
Why?
|
14-3-3 Proteins | 1 | 2021 | 143 | 0.720 |
Why?
|
Fatty Liver | 2 | 2013 | 252 | 0.710 |
Why?
|
Intercellular Signaling Peptides and Proteins | 6 | 2013 | 670 | 0.700 |
Why?
|
Heart Defects, Congenital | 3 | 2018 | 1776 | 0.700 |
Why?
|
Pyrazines | 4 | 2007 | 508 | 0.690 |
Why?
|
Face | 1 | 2022 | 286 | 0.690 |
Why?
|
Epidermal Cyst | 1 | 2019 | 46 | 0.680 |
Why?
|
Tears | 2 | 2020 | 181 | 0.670 |
Why?
|
Glucose Clamp Technique | 9 | 2010 | 92 | 0.670 |
Why?
|
Lighting | 1 | 2019 | 26 | 0.670 |
Why?
|
Adhesives | 1 | 2018 | 12 | 0.650 |
Why?
|
Female | 80 | 2024 | 147292 | 0.650 |
Why?
|
Lacerations | 1 | 2019 | 34 | 0.640 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2022 | 5531 | 0.640 |
Why?
|
Mouth Mucosa | 1 | 2019 | 218 | 0.640 |
Why?
|
Skin Abnormalities | 1 | 2018 | 27 | 0.610 |
Why?
|
Ocular Motility Disorders | 1 | 2018 | 46 | 0.610 |
Why?
|
Paracentesis | 2 | 2019 | 20 | 0.610 |
Why?
|
Adult | 56 | 2024 | 80709 | 0.610 |
Why?
|
Betacoronavirus | 2 | 2020 | 532 | 0.600 |
Why?
|
AMP-Activated Protein Kinases | 5 | 2020 | 409 | 0.600 |
Why?
|
Histiocytosis, Sinus | 1 | 2018 | 88 | 0.600 |
Why?
|
Prospective Studies | 18 | 2023 | 13310 | 0.600 |
Why?
|
Ocular Hypertension | 1 | 2017 | 25 | 0.590 |
Why?
|
Neurilemmoma | 2 | 2018 | 128 | 0.590 |
Why?
|
Inflammasomes | 5 | 2021 | 167 | 0.580 |
Why?
|
Incretins | 2 | 2018 | 28 | 0.580 |
Why?
|
PPAR alpha | 3 | 2017 | 62 | 0.560 |
Why?
|
Cardiovascular System | 1 | 2018 | 144 | 0.560 |
Why?
|
Decompression, Surgical | 1 | 2017 | 148 | 0.560 |
Why?
|
Emphysema | 1 | 2017 | 87 | 0.550 |
Why?
|
Muscle Proteins | 2 | 2013 | 567 | 0.550 |
Why?
|
Cataract Extraction | 1 | 2018 | 182 | 0.550 |
Why?
|
Needles | 1 | 2016 | 107 | 0.540 |
Why?
|
Gene Expression Regulation | 6 | 2021 | 4071 | 0.530 |
Why?
|
Abnormalities, Multiple | 1 | 2022 | 1018 | 0.530 |
Why?
|
Young Adult | 24 | 2024 | 22140 | 0.530 |
Why?
|
Hypergammaglobulinemia | 1 | 2015 | 20 | 0.530 |
Why?
|
Child | 26 | 2024 | 30200 | 0.520 |
Why?
|
Glucose | 8 | 2011 | 1267 | 0.520 |
Why?
|
Immunoglobulin G | 2 | 2019 | 1061 | 0.520 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 36 | 0.520 |
Why?
|
Prefrontal Cortex | 2 | 2017 | 237 | 0.510 |
Why?
|
Urogenital Abnormalities | 1 | 2018 | 177 | 0.510 |
Why?
|
Dry Eye Syndromes | 1 | 2019 | 286 | 0.510 |
Why?
|
Adenocarcinoma, Sebaceous | 4 | 2022 | 66 | 0.510 |
Why?
|
Middle Aged | 54 | 2024 | 89535 | 0.510 |
Why?
|
Metformin | 3 | 2014 | 390 | 0.500 |
Why?
|
Fasciitis, Necrotizing | 1 | 2015 | 37 | 0.500 |
Why?
|
Tertiary Care Centers | 3 | 2024 | 421 | 0.490 |
Why?
|
Anus, Imperforate | 1 | 2014 | 12 | 0.490 |
Why?
|
Myocardial Reperfusion Injury | 2 | 2016 | 202 | 0.490 |
Why?
|
Fluorobenzenes | 1 | 2014 | 39 | 0.480 |
Why?
|
Radius | 1 | 2014 | 43 | 0.480 |
Why?
|
Tuberculosis, Ocular | 1 | 2014 | 4 | 0.480 |
Why?
|
Hypolipidemic Agents | 4 | 2009 | 197 | 0.480 |
Why?
|
Eye Infections, Parasitic | 3 | 2018 | 7 | 0.470 |
Why?
|
Lipoxins | 3 | 2012 | 20 | 0.470 |
Why?
|
Diseases in Twins | 1 | 2014 | 100 | 0.460 |
Why?
|
Twins, Monozygotic | 1 | 2014 | 132 | 0.460 |
Why?
|
Tomography, X-Ray Computed | 16 | 2022 | 7738 | 0.450 |
Why?
|
Lipids | 3 | 2012 | 661 | 0.450 |
Why?
|
PTEN Phosphohydrolase | 4 | 2014 | 1000 | 0.450 |
Why?
|
Glucosides | 3 | 2018 | 69 | 0.450 |
Why?
|
India | 9 | 2021 | 306 | 0.440 |
Why?
|
Uveal Neoplasms | 3 | 2020 | 188 | 0.440 |
Why?
|
MicroRNAs | 5 | 2020 | 2955 | 0.440 |
Why?
|
Benzhydryl Compounds | 3 | 2018 | 88 | 0.440 |
Why?
|
Splanchnic Circulation | 2 | 2003 | 59 | 0.430 |
Why?
|
Spine | 1 | 2014 | 307 | 0.430 |
Why?
|
Purines | 1 | 2014 | 275 | 0.430 |
Why?
|
Drug Therapy, Combination | 10 | 2018 | 2348 | 0.420 |
Why?
|
Lipogenesis | 1 | 2012 | 79 | 0.420 |
Why?
|
Trachea | 1 | 2014 | 271 | 0.420 |
Why?
|
Cardiotonic Agents | 2 | 2016 | 159 | 0.410 |
Why?
|
Adolescent | 23 | 2024 | 32336 | 0.410 |
Why?
|
Biomarkers, Tumor | 9 | 2021 | 10627 | 0.410 |
Why?
|
Eye Injuries, Penetrating | 3 | 2017 | 22 | 0.410 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2017 | 991 | 0.400 |
Why?
|
Cardiovascular Diseases | 3 | 2018 | 2352 | 0.400 |
Why?
|
Nasolacrimal Duct | 3 | 2018 | 44 | 0.400 |
Why?
|
Nitric Oxide Synthase | 2 | 2010 | 322 | 0.400 |
Why?
|
Retrospective Studies | 18 | 2024 | 39512 | 0.400 |
Why?
|
Up-Regulation | 3 | 2014 | 2480 | 0.390 |
Why?
|
Carotid Arteries | 1 | 2013 | 256 | 0.390 |
Why?
|
Carotid Artery Diseases | 1 | 2013 | 202 | 0.380 |
Why?
|
Obesity | 6 | 2018 | 2995 | 0.380 |
Why?
|
Cicatrix | 2 | 2023 | 204 | 0.380 |
Why?
|
Esophagus | 1 | 2014 | 557 | 0.370 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 1124 | 0.370 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2020 | 21 | 0.370 |
Why?
|
Ophthalmologic Surgical Procedures | 5 | 2020 | 144 | 0.370 |
Why?
|
Muscle Cells | 1 | 2010 | 37 | 0.360 |
Why?
|
Acyl Coenzyme A | 2 | 2010 | 34 | 0.350 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 5 | 2018 | 67 | 0.350 |
Why?
|
Fibroblast Growth Factors | 1 | 2011 | 264 | 0.350 |
Why?
|
Mutation | 4 | 2021 | 15642 | 0.340 |
Why?
|
Thinness | 1 | 2010 | 84 | 0.340 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 3836 | 0.340 |
Why?
|
Phosphodiesterase 3 Inhibitors | 3 | 2014 | 8 | 0.340 |
Why?
|
Aspergillosis | 2 | 2022 | 246 | 0.340 |
Why?
|
Treatment Outcome | 18 | 2020 | 34238 | 0.340 |
Why?
|
Dipeptidyl Peptidase 4 | 3 | 2019 | 57 | 0.340 |
Why?
|
Diagnosis, Differential | 12 | 2018 | 4862 | 0.340 |
Why?
|
Quinazolines | 1 | 2014 | 934 | 0.340 |
Why?
|
Prednisolone | 4 | 2018 | 123 | 0.340 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 3 | 2020 | 434 | 0.330 |
Why?
|
Proteins | 4 | 2004 | 1989 | 0.330 |
Why?
|
Tetrazoles | 3 | 2014 | 107 | 0.320 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 3623 | 0.320 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2019 | 117 | 0.320 |
Why?
|
Myocardium | 6 | 2020 | 1335 | 0.310 |
Why?
|
Ophthalmology | 2 | 2021 | 201 | 0.310 |
Why?
|
Quality of Life | 1 | 2022 | 4721 | 0.310 |
Why?
|
Carcinoma, Adenoid Cystic | 3 | 2021 | 442 | 0.300 |
Why?
|
Adamantane | 2 | 2018 | 32 | 0.300 |
Why?
|
Glucocorticoids | 3 | 2018 | 631 | 0.300 |
Why?
|
Suture Techniques | 2 | 2020 | 317 | 0.300 |
Why?
|
Linagliptin | 2 | 2019 | 4 | 0.300 |
Why?
|
Dipeptides | 2 | 2018 | 96 | 0.290 |
Why?
|
Neoplasm Staging | 3 | 2022 | 13882 | 0.290 |
Why?
|
Glucose Tolerance Test | 6 | 2010 | 225 | 0.290 |
Why?
|
Reflex, Abnormal | 2 | 2018 | 20 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 5716 | 0.280 |
Why?
|
Myocytes, Cardiac | 4 | 2017 | 823 | 0.280 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 881 | 0.280 |
Why?
|
Oxazoles | 2 | 2017 | 63 | 0.280 |
Why?
|
Eye | 2 | 2022 | 291 | 0.270 |
Why?
|
Dyslipidemias | 1 | 2009 | 242 | 0.270 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 396 | 0.270 |
Why?
|
Triglycerides | 5 | 2012 | 621 | 0.270 |
Why?
|
Sulfonamides | 2 | 2014 | 1896 | 0.260 |
Why?
|
Cardiovascular Agents | 2 | 2018 | 139 | 0.260 |
Why?
|
Thiophenes | 2 | 2017 | 151 | 0.260 |
Why?
|
Ultrasonography | 5 | 2018 | 1926 | 0.250 |
Why?
|
Aged | 24 | 2024 | 72902 | 0.250 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2011 | 629 | 0.250 |
Why?
|
Sodium-Glucose Transporter 2 | 3 | 2021 | 15 | 0.240 |
Why?
|
Hormones, Ectopic | 1 | 2004 | 10 | 0.240 |
Why?
|
Follow-Up Studies | 11 | 2024 | 15198 | 0.240 |
Why?
|
Point-of-Care Systems | 1 | 2007 | 217 | 0.240 |
Why?
|
Albendazole | 3 | 2018 | 29 | 0.230 |
Why?
|
Animals | 26 | 2021 | 61014 | 0.230 |
Why?
|
Optic Nerve | 2 | 2023 | 136 | 0.230 |
Why?
|
Rare Diseases | 3 | 2022 | 360 | 0.230 |
Why?
|
Eye, Artificial | 1 | 2023 | 16 | 0.220 |
Why?
|
Diabetes Mellitus, Type 1 | 4 | 2021 | 847 | 0.220 |
Why?
|
Smoking | 1 | 2012 | 2525 | 0.220 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2003 | 50 | 0.220 |
Why?
|
Cadherins | 3 | 2017 | 675 | 0.220 |
Why?
|
Sutures | 2 | 2020 | 88 | 0.220 |
Why?
|
Muscles | 2 | 2004 | 423 | 0.220 |
Why?
|
Receptors, Glucagon | 4 | 2012 | 36 | 0.210 |
Why?
|
Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2022 | 6 | 0.210 |
Why?
|
Body Weight | 3 | 2012 | 1321 | 0.210 |
Why?
|
Cyclin B1 | 1 | 2022 | 59 | 0.210 |
Why?
|
Viscera | 1 | 2002 | 89 | 0.210 |
Why?
|
Visual Acuity | 4 | 2019 | 858 | 0.200 |
Why?
|
Coronavirus Infections | 2 | 2020 | 654 | 0.200 |
Why?
|
Dermatofibrosarcoma | 1 | 2022 | 73 | 0.200 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 723 | 0.200 |
Why?
|
Pyrimidines | 1 | 2014 | 3609 | 0.200 |
Why?
|
Ketosis | 1 | 2021 | 16 | 0.200 |
Why?
|
Taenia solium | 1 | 2021 | 7 | 0.200 |
Why?
|
Melanoma | 5 | 2020 | 5445 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2021 | 1571 | 0.200 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2020 | 224 | 0.200 |
Why?
|
Eye Diseases | 1 | 2023 | 129 | 0.200 |
Why?
|
Mannans | 1 | 2021 | 31 | 0.190 |
Why?
|
Infant | 9 | 2024 | 13818 | 0.190 |
Why?
|
Diabetes Mellitus, Experimental | 4 | 2019 | 230 | 0.190 |
Why?
|
Saccharum | 1 | 2020 | 10 | 0.190 |
Why?
|
Ethmoid Sinus | 1 | 2020 | 27 | 0.190 |
Why?
|
Pandemics | 2 | 2020 | 1627 | 0.180 |
Why?
|
Signal Transduction | 13 | 2020 | 12151 | 0.180 |
Why?
|
Adipocytes, Brown | 1 | 2020 | 28 | 0.180 |
Why?
|
Homeodomain Proteins | 2 | 2017 | 1149 | 0.180 |
Why?
|
Electroacupuncture | 1 | 2020 | 35 | 0.180 |
Why?
|
Cells, Cultured | 8 | 2020 | 5670 | 0.180 |
Why?
|
Body Mass Index | 5 | 2011 | 2299 | 0.180 |
Why?
|
Mitochondria | 2 | 2004 | 1307 | 0.180 |
Why?
|
Fasting | 4 | 2017 | 356 | 0.180 |
Why?
|
Hypoglycemia | 3 | 2014 | 215 | 0.180 |
Why?
|
Administration, Topical | 1 | 2020 | 266 | 0.180 |
Why?
|
Accidents, Traffic | 1 | 2020 | 122 | 0.170 |
Why?
|
Wounds, Penetrating | 1 | 2020 | 93 | 0.170 |
Why?
|
Phosphorylation | 6 | 2020 | 4887 | 0.170 |
Why?
|
Hemangioma | 1 | 2021 | 159 | 0.170 |
Why?
|
Time Factors | 12 | 2018 | 13266 | 0.170 |
Why?
|
Adipocytes, White | 2 | 2020 | 32 | 0.170 |
Why?
|
Blepharoplasty | 1 | 2020 | 39 | 0.170 |
Why?
|
Prognosis | 8 | 2023 | 22249 | 0.170 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2020 | 119 | 0.170 |
Why?
|
Child, Preschool | 9 | 2024 | 16792 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2020 | 2084 | 0.170 |
Why?
|
Cyclin D1 | 1 | 2022 | 582 | 0.170 |
Why?
|
Diabetic Ketoacidosis | 1 | 2021 | 151 | 0.170 |
Why?
|
Mucous Membrane | 1 | 2020 | 276 | 0.170 |
Why?
|
Receptor, Notch1 | 1 | 2021 | 221 | 0.170 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 2317 | 0.170 |
Why?
|
Lymphangioma | 1 | 2019 | 36 | 0.170 |
Why?
|
Adenoma, Pleomorphic | 2 | 2016 | 63 | 0.170 |
Why?
|
Botulinum Toxins, Type A | 1 | 2022 | 193 | 0.170 |
Why?
|
Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 6 | 0.170 |
Why?
|
Propranolol | 1 | 2019 | 156 | 0.170 |
Why?
|
Kidney | 2 | 2018 | 2200 | 0.170 |
Why?
|
Liposarcoma | 1 | 2021 | 244 | 0.160 |
Why?
|
Eyelashes | 1 | 2018 | 3 | 0.160 |
Why?
|
Administration, Ophthalmic | 1 | 2018 | 5 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2003 | 675 | 0.160 |
Why?
|
Ventricular Function, Left | 2 | 2020 | 615 | 0.160 |
Why?
|
Thiazoles | 1 | 2003 | 732 | 0.160 |
Why?
|
Cleft Palate | 1 | 2020 | 137 | 0.160 |
Why?
|
Cleft Lip | 1 | 2020 | 139 | 0.160 |
Why?
|
Ventricular Remodeling | 1 | 2020 | 253 | 0.160 |
Why?
|
Conjunctivitis | 1 | 2018 | 28 | 0.160 |
Why?
|
Histoplasma | 1 | 2018 | 30 | 0.160 |
Why?
|
Adipose Tissue, Brown | 2 | 2017 | 114 | 0.160 |
Why?
|
Pilot Projects | 2 | 2022 | 2868 | 0.160 |
Why?
|
Echinococcosis | 1 | 2018 | 15 | 0.160 |
Why?
|
Endemic Diseases | 1 | 2018 | 70 | 0.160 |
Why?
|
Antiprotozoal Agents | 1 | 2018 | 41 | 0.160 |
Why?
|
Salivary Ducts | 1 | 2018 | 56 | 0.160 |
Why?
|
Diplopia | 1 | 2018 | 60 | 0.160 |
Why?
|
Conjunctival Diseases | 1 | 2018 | 32 | 0.150 |
Why?
|
Vimentin | 1 | 2019 | 252 | 0.150 |
Why?
|
Mice, Inbred C57BL | 9 | 2021 | 7173 | 0.150 |
Why?
|
Bleomycin | 1 | 2019 | 478 | 0.150 |
Why?
|
Tissue and Organ Harvesting | 1 | 2019 | 151 | 0.150 |
Why?
|
Histoplasmosis | 1 | 2018 | 73 | 0.150 |
Why?
|
Eye Infections, Fungal | 1 | 2018 | 69 | 0.150 |
Why?
|
Heart | 2 | 2016 | 1255 | 0.150 |
Why?
|
Aspartate Aminotransferases | 2 | 2011 | 155 | 0.150 |
Why?
|
Subcutaneous Fat | 1 | 2018 | 92 | 0.150 |
Why?
|
Cold Temperature | 1 | 2017 | 131 | 0.150 |
Why?
|
Immunohistochemistry | 9 | 2021 | 7704 | 0.150 |
Why?
|
Thermogenesis | 1 | 2017 | 51 | 0.150 |
Why?
|
Healthy Volunteers | 1 | 2018 | 190 | 0.150 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 333 | 0.150 |
Why?
|
Myxoma | 1 | 2017 | 64 | 0.140 |
Why?
|
Myocardial Infarction | 4 | 2019 | 1498 | 0.140 |
Why?
|
Orbital Fractures | 1 | 2017 | 44 | 0.140 |
Why?
|
Cysts | 2 | 2019 | 202 | 0.140 |
Why?
|
Alanine Transaminase | 2 | 2011 | 240 | 0.140 |
Why?
|
Hyperglycemia | 3 | 2017 | 338 | 0.140 |
Why?
|
Remission, Spontaneous | 1 | 2016 | 121 | 0.140 |
Why?
|
Liraglutide | 1 | 2016 | 17 | 0.140 |
Why?
|
Weight Gain | 2 | 2014 | 473 | 0.140 |
Why?
|
Emergency Treatment | 1 | 2017 | 108 | 0.140 |
Why?
|
Biomarkers | 4 | 2020 | 5176 | 0.140 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2013 | 435 | 0.140 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2017 | 112 | 0.140 |
Why?
|
Vitreous Body | 1 | 2016 | 119 | 0.140 |
Why?
|
Mice | 13 | 2021 | 35331 | 0.140 |
Why?
|
RNA, Neoplasm | 1 | 2019 | 797 | 0.140 |
Why?
|
C-Peptide | 4 | 2007 | 116 | 0.140 |
Why?
|
Kidney Tubules, Proximal | 1 | 2017 | 144 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 2734 | 0.130 |
Why?
|
Gene Regulatory Networks | 1 | 2020 | 683 | 0.130 |
Why?
|
Salivary Gland Neoplasms | 2 | 2018 | 493 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 558 | 0.130 |
Why?
|
Diabetic Nephropathies | 1 | 2018 | 185 | 0.130 |
Why?
|
Protective Agents | 1 | 2016 | 51 | 0.130 |
Why?
|
Craniofacial Abnormalities | 1 | 2017 | 249 | 0.130 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2018 | 121 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 491 | 0.130 |
Why?
|
RNA Interference | 3 | 2017 | 1411 | 0.130 |
Why?
|
Sclerosis | 1 | 2015 | 81 | 0.130 |
Why?
|
Wounds, Nonpenetrating | 1 | 2017 | 184 | 0.130 |
Why?
|
Immunologic Factors | 1 | 2019 | 667 | 0.130 |
Why?
|
Consensus | 1 | 2020 | 1087 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2017 | 150 | 0.130 |
Why?
|
Nose | 1 | 2017 | 202 | 0.130 |
Why?
|
Anti-Bacterial Agents | 3 | 2018 | 3096 | 0.130 |
Why?
|
DNA, Neoplasm | 1 | 2021 | 1929 | 0.130 |
Why?
|
RNA, Messenger | 5 | 2015 | 6224 | 0.130 |
Why?
|
Neoplasm Invasiveness | 1 | 2023 | 4062 | 0.130 |
Why?
|
Craniocerebral Trauma | 1 | 2016 | 135 | 0.130 |
Why?
|
Cyclic AMP | 2 | 2012 | 369 | 0.120 |
Why?
|
Tumor Suppressor Proteins | 2 | 2020 | 1878 | 0.120 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2015 | 94 | 0.120 |
Why?
|
Diet, Western | 1 | 2014 | 23 | 0.120 |
Why?
|
Rosuvastatin Calcium | 1 | 2014 | 46 | 0.120 |
Why?
|
Global Health | 1 | 2020 | 696 | 0.120 |
Why?
|
Fibroblasts | 2 | 2018 | 1693 | 0.120 |
Why?
|
Dietary Fats | 2 | 2008 | 351 | 0.120 |
Why?
|
Drainage | 2 | 2014 | 429 | 0.120 |
Why?
|
Disease Models, Animal | 7 | 2020 | 7429 | 0.120 |
Why?
|
Tomography, Optical Coherence | 1 | 2019 | 564 | 0.120 |
Why?
|
Debridement | 1 | 2015 | 127 | 0.120 |
Why?
|
Curettage | 1 | 2014 | 21 | 0.120 |
Why?
|
Equipment Design | 1 | 2018 | 1232 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 5 | 2023 | 7962 | 0.120 |
Why?
|
Pain | 1 | 2022 | 1694 | 0.120 |
Why?
|
Aged, 80 and over | 8 | 2024 | 30813 | 0.120 |
Why?
|
Skin Transplantation | 1 | 2015 | 180 | 0.120 |
Why?
|
Models, Genetic | 1 | 2018 | 1132 | 0.110 |
Why?
|
Polyethylene | 1 | 2013 | 22 | 0.110 |
Why?
|
Genetic Association Studies | 1 | 2018 | 1091 | 0.110 |
Why?
|
Skin Neoplasms | 2 | 2022 | 4776 | 0.110 |
Why?
|
Intubation | 1 | 2013 | 40 | 0.110 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2013 | 115 | 0.110 |
Why?
|
Orbital Cellulitis | 1 | 2013 | 18 | 0.110 |
Why?
|
Biopsy | 6 | 2021 | 3490 | 0.110 |
Why?
|
Energy Metabolism | 2 | 2018 | 1008 | 0.110 |
Why?
|
Polymerase Chain Reaction | 3 | 2014 | 3238 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 10257 | 0.110 |
Why?
|
Cytodiagnosis | 1 | 2014 | 224 | 0.110 |
Why?
|
Metabolic Syndrome | 1 | 2016 | 379 | 0.110 |
Why?
|
Alkylating Agents | 1 | 2012 | 78 | 0.110 |
Why?
|
Retina | 2 | 2013 | 548 | 0.100 |
Why?
|
Coloring Agents | 1 | 2013 | 243 | 0.100 |
Why?
|
Wnt Signaling Pathway | 1 | 2015 | 446 | 0.100 |
Why?
|
Eye Infections, Bacterial | 1 | 2013 | 93 | 0.100 |
Why?
|
Apoptosis | 5 | 2020 | 7759 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 9067 | 0.100 |
Why?
|
Inflammation Mediators | 3 | 2020 | 430 | 0.100 |
Why?
|
DNA Damage | 1 | 2020 | 1989 | 0.100 |
Why?
|
Mitomycin | 1 | 2012 | 207 | 0.100 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1083 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2020 | 1348 | 0.100 |
Why?
|
Ubiquitin | 1 | 2013 | 342 | 0.100 |
Why?
|
Postoperative Complications | 3 | 2023 | 5838 | 0.100 |
Why?
|
Tumor Burden | 1 | 2017 | 2019 | 0.090 |
Why?
|
Antitubercular Agents | 1 | 2014 | 345 | 0.090 |
Why?
|
Epinephrine | 3 | 2021 | 256 | 0.090 |
Why?
|
Disease Progression | 3 | 2019 | 6891 | 0.090 |
Why?
|
Treatment Failure | 1 | 2014 | 1433 | 0.090 |
Why?
|
Human papillomavirus 16 | 1 | 2012 | 259 | 0.090 |
Why?
|
Hepatocytes | 1 | 2013 | 353 | 0.090 |
Why?
|
Logistic Models | 1 | 2018 | 3522 | 0.090 |
Why?
|
Diabetic Retinopathy | 1 | 2013 | 179 | 0.090 |
Why?
|
Reference Values | 5 | 2004 | 1129 | 0.090 |
Why?
|
Receptors, Cell Surface | 2 | 2004 | 879 | 0.090 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2013 | 593 | 0.090 |
Why?
|
Diglycerides | 1 | 2010 | 37 | 0.090 |
Why?
|
DNA, Viral | 1 | 2012 | 674 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2014 | 2662 | 0.090 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 5113 | 0.090 |
Why?
|
Edema | 1 | 2011 | 269 | 0.090 |
Why?
|
Nausea | 1 | 2011 | 535 | 0.080 |
Why?
|
Infant, Newborn | 3 | 2017 | 8566 | 0.080 |
Why?
|
Mycobacterium tuberculosis | 1 | 2014 | 464 | 0.080 |
Why?
|
Gene Silencing | 1 | 2012 | 840 | 0.080 |
Why?
|
Injections, Intralesional | 2 | 2019 | 163 | 0.080 |
Why?
|
Multimodal Imaging | 1 | 2013 | 553 | 0.080 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 521 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2004 | 1589 | 0.080 |
Why?
|
Lower Extremity | 1 | 2011 | 298 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 770 | 0.080 |
Why?
|
Helper Viruses | 1 | 2008 | 56 | 0.080 |
Why?
|
Texas | 3 | 2012 | 6460 | 0.080 |
Why?
|
Hormones | 4 | 2007 | 276 | 0.080 |
Why?
|
beta Catenin | 1 | 2012 | 697 | 0.080 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 1219 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2010 | 570 | 0.080 |
Why?
|
Triazoles | 1 | 2012 | 630 | 0.080 |
Why?
|
Papillomavirus Infections | 2 | 2018 | 1013 | 0.080 |
Why?
|
Glucagon | 2 | 2006 | 201 | 0.080 |
Why?
|
Surgical Flaps | 1 | 2015 | 959 | 0.080 |
Why?
|
Leptin | 2 | 2013 | 307 | 0.080 |
Why?
|
Disease Management | 1 | 2014 | 1106 | 0.080 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 3518 | 0.080 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 1094 | 0.080 |
Why?
|
Receptors, Adiponectin | 2 | 2004 | 12 | 0.080 |
Why?
|
Anthelmintics | 2 | 2018 | 69 | 0.070 |
Why?
|
Eating | 2 | 2008 | 431 | 0.070 |
Why?
|
Adipose Tissue, White | 2 | 2018 | 105 | 0.070 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 1335 | 0.070 |
Why?
|
Repressor Proteins | 1 | 2015 | 1699 | 0.070 |
Why?
|
Tandem Mass Spectrometry | 1 | 2010 | 385 | 0.070 |
Why?
|
Cholesterol | 3 | 2012 | 680 | 0.070 |
Why?
|
Fenofibrate | 1 | 2007 | 58 | 0.070 |
Why?
|
Free Radical Scavengers | 1 | 2007 | 83 | 0.070 |
Why?
|
Carcinoma | 1 | 2018 | 2601 | 0.070 |
Why?
|
Heart Diseases | 1 | 2013 | 756 | 0.070 |
Why?
|
Nitric Oxide | 1 | 2010 | 659 | 0.070 |
Why?
|
Multienzyme Complexes | 1 | 2007 | 222 | 0.070 |
Why?
|
Gastric Emptying | 1 | 2006 | 101 | 0.070 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 417 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 4646 | 0.070 |
Why?
|
Antifungal Agents | 2 | 2022 | 854 | 0.060 |
Why?
|
Fat Emulsions, Intravenous | 2 | 2003 | 70 | 0.060 |
Why?
|
Fibrosis | 2 | 2020 | 806 | 0.060 |
Why?
|
Insulin-Secreting Cells | 1 | 2006 | 165 | 0.060 |
Why?
|
Circadian Rhythm | 1 | 2007 | 339 | 0.060 |
Why?
|
Adenylate Kinase | 1 | 2004 | 35 | 0.060 |
Why?
|
Resistin | 1 | 2004 | 43 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 2 | 2018 | 471 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 2210 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2005 | 247 | 0.060 |
Why?
|
Models, Biological | 1 | 2012 | 3255 | 0.060 |
Why?
|
Infant, Low Birth Weight | 1 | 2004 | 184 | 0.060 |
Why?
|
Adenoviridae | 1 | 2008 | 1455 | 0.050 |
Why?
|
Sebaceous Glands | 1 | 2022 | 13 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 1583 | 0.050 |
Why?
|
Neoplasm Grading | 2 | 2020 | 1808 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2018 | 1800 | 0.050 |
Why?
|
Cholesterol, HDL | 1 | 2004 | 364 | 0.050 |
Why?
|
3' Untranslated Regions | 2 | 2013 | 345 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6269 | 0.050 |
Why?
|
Mice, Knockout | 3 | 2017 | 5804 | 0.050 |
Why?
|
Mexican Americans | 1 | 2004 | 328 | 0.050 |
Why?
|
Syndrome | 2 | 2017 | 1382 | 0.050 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 2 | 2012 | 242 | 0.050 |
Why?
|
Fatty Acids | 1 | 2004 | 460 | 0.050 |
Why?
|
Corticosterone | 1 | 2021 | 116 | 0.050 |
Why?
|
Injections, Intravenous | 1 | 2002 | 578 | 0.050 |
Why?
|
Streptozocin | 1 | 2021 | 73 | 0.050 |
Why?
|
Survival Rate | 3 | 2022 | 12451 | 0.050 |
Why?
|
Extracellular Matrix | 1 | 2004 | 561 | 0.050 |
Why?
|
Galactose | 1 | 2021 | 87 | 0.050 |
Why?
|
Ketones | 1 | 2021 | 57 | 0.050 |
Why?
|
Osmolar Concentration | 3 | 2007 | 205 | 0.050 |
Why?
|
Voriconazole | 1 | 2021 | 114 | 0.050 |
Why?
|
Genetic Therapy | 1 | 2008 | 1630 | 0.050 |
Why?
|
Organelle Biogenesis | 1 | 2020 | 31 | 0.050 |
Why?
|
Incidence | 2 | 2024 | 5904 | 0.050 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2020 | 55 | 0.040 |
Why?
|
Vision Disorders | 1 | 2022 | 243 | 0.040 |
Why?
|
Kinetics | 1 | 2003 | 2098 | 0.040 |
Why?
|
Cell Survival | 2 | 2017 | 3062 | 0.040 |
Why?
|
Epithelioid Cells | 1 | 2020 | 43 | 0.040 |
Why?
|
Transfection | 2 | 2017 | 2989 | 0.040 |
Why?
|
Thyroid Gland | 1 | 2022 | 358 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2004 | 1057 | 0.040 |
Why?
|
Coronary Disease | 1 | 2004 | 811 | 0.040 |
Why?
|
Collagen | 2 | 2018 | 748 | 0.040 |
Why?
|
Sclerosing Solutions | 1 | 2019 | 27 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2003 | 590 | 0.040 |
Why?
|
Water | 1 | 2021 | 376 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2004 | 1642 | 0.040 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2002 | 635 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2022 | 4925 | 0.040 |
Why?
|
Awareness | 1 | 1999 | 124 | 0.040 |
Why?
|
Prolapse | 1 | 2018 | 13 | 0.040 |
Why?
|
Taenia | 1 | 2018 | 13 | 0.040 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 352 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2018 | 158 | 0.040 |
Why?
|
Oligopeptides | 1 | 2020 | 431 | 0.040 |
Why?
|
Cysticercus | 1 | 2017 | 5 | 0.040 |
Why?
|
Immunoblotting | 2 | 2012 | 900 | 0.040 |
Why?
|
STAT1 Transcription Factor | 1 | 2018 | 159 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 627 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2018 | 616 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2022 | 709 | 0.040 |
Why?
|
Mice, Obese | 1 | 2017 | 105 | 0.040 |
Why?
|
Cytoprotection | 1 | 2017 | 66 | 0.040 |
Why?
|
Calibration | 1 | 2018 | 341 | 0.040 |
Why?
|
Cytochromes c | 1 | 2017 | 118 | 0.040 |
Why?
|
Metals | 1 | 2017 | 156 | 0.040 |
Why?
|
Polysaccharides | 1 | 2018 | 201 | 0.040 |
Why?
|
Metabolomics | 1 | 2020 | 487 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2019 | 10093 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 5030 | 0.030 |
Why?
|
Environment | 1 | 2017 | 184 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2018 | 250 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2018 | 589 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 2013 | 1410 | 0.030 |
Why?
|
Diet | 1 | 2004 | 1476 | 0.030 |
Why?
|
DNA, Mitochondrial | 1 | 2017 | 318 | 0.030 |
Why?
|
Caspase 3 | 1 | 2017 | 480 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2019 | 734 | 0.030 |
Why?
|
Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 42 | 0.030 |
Why?
|
DNA Methylation | 2 | 2018 | 2736 | 0.030 |
Why?
|
Age Distribution | 1 | 2017 | 715 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2018 | 498 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 5242 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 9010 | 0.030 |
Why?
|
Surgery, Plastic | 1 | 2020 | 352 | 0.030 |
Why?
|
Stroke Volume | 1 | 2017 | 605 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1007 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2017 | 501 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 1999 | 766 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2017 | 731 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2013 | 5031 | 0.030 |
Why?
|
Esthetics | 1 | 2015 | 198 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2015 | 214 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2018 | 2327 | 0.030 |
Why?
|
Societies, Medical | 1 | 2020 | 1399 | 0.030 |
Why?
|
Forkhead Box Protein L2 | 1 | 2013 | 17 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2006 | 7303 | 0.030 |
Why?
|
Patient Compliance | 1 | 2018 | 685 | 0.030 |
Why?
|
Lymphoscintigraphy | 1 | 2013 | 35 | 0.030 |
Why?
|
Amblyopia | 1 | 2013 | 96 | 0.030 |
Why?
|
Down-Regulation | 1 | 2018 | 2114 | 0.030 |
Why?
|
Binding, Competitive | 1 | 2013 | 301 | 0.030 |
Why?
|
Ceftriaxone | 1 | 2013 | 71 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2013 | 87 | 0.030 |
Why?
|
Eye Movements | 1 | 2013 | 103 | 0.030 |
Why?
|
Therapeutic Irrigation | 1 | 2012 | 90 | 0.030 |
Why?
|
Refractive Errors | 1 | 2013 | 84 | 0.030 |
Why?
|
Strabismus | 1 | 2013 | 158 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2013 | 361 | 0.030 |
Why?
|
Metronidazole | 1 | 2013 | 154 | 0.030 |
Why?
|
Isoquinolines | 1 | 2012 | 119 | 0.030 |
Why?
|
Photography | 1 | 2013 | 137 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2013 | 418 | 0.030 |
Why?
|
Eye Enucleation | 1 | 2012 | 87 | 0.030 |
Why?
|
Choroid | 1 | 2012 | 39 | 0.030 |
Why?
|
Protein Binding | 1 | 2018 | 3483 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 949 | 0.020 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2013 | 319 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 2871 | 0.020 |
Why?
|
Vancomycin | 1 | 2013 | 281 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2013 | 811 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2017 | 1158 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 9324 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 4544 | 0.020 |
Why?
|
Developing Countries | 1 | 2012 | 329 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 2223 | 0.020 |
Why?
|
Binding Sites | 1 | 2013 | 2210 | 0.020 |
Why?
|
Genotype | 1 | 2017 | 4168 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 2 | 1999 | 159 | 0.020 |
Why?
|
Human Growth Hormone | 2 | 1999 | 84 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 2013 | 1020 | 0.020 |
Why?
|
Radiography | 1 | 2013 | 1944 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3666 | 0.020 |
Why?
|
Brain | 1 | 2021 | 4194 | 0.020 |
Why?
|
Hydrocortisone | 2 | 1999 | 389 | 0.020 |
Why?
|
Risk Assessment | 1 | 2020 | 7170 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 4895 | 0.020 |
Why?
|
Age Factors | 1 | 2017 | 5506 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 3596 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 5116 | 0.020 |
Why?
|
Gene Expression | 1 | 2014 | 3594 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2013 | 1444 | 0.020 |
Why?
|
Cell Line | 1 | 2013 | 5132 | 0.020 |
Why?
|
Phenotype | 1 | 2017 | 6404 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2012 | 3109 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2013 | 2021 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2004 | 195 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 1432 | 0.020 |
Why?
|
Systole | 1 | 2004 | 207 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 2004 | 235 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 18267 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2004 | 539 | 0.010 |
Why?
|
Emulsions | 1 | 2003 | 85 | 0.010 |
Why?
|
Soybean Oil | 1 | 2003 | 66 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 6245 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2008 | 1712 | 0.010 |
Why?
|
Phospholipids | 1 | 2003 | 179 | 0.010 |
Why?
|
Calorimetry, Indirect | 1 | 2002 | 62 | 0.010 |
Why?
|
Tritium | 1 | 2002 | 206 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 775 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2012 | 2917 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 156 | 0.010 |
Why?
|
Lipid Peroxidation | 1 | 2002 | 159 | 0.010 |
Why?
|
Biological Transport | 1 | 2002 | 605 | 0.010 |
Why?
|
Drug Resistance | 1 | 2002 | 600 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2002 | 729 | 0.010 |
Why?
|
Sex Factors | 1 | 2004 | 2217 | 0.010 |
Why?
|
Models, Statistical | 1 | 2004 | 1205 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 2520 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2004 | 1699 | 0.010 |
Why?
|
Norepinephrine | 1 | 1998 | 277 | 0.010 |
Why?
|
Perception | 1 | 1999 | 358 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2013 | 7908 | 0.010 |
Why?
|
Regression Analysis | 1 | 1998 | 1569 | 0.010 |
Why?
|
Inflammation | 1 | 2004 | 2572 | 0.010 |
Why?
|
Homeostasis | 1 | 1998 | 947 | 0.010 |
Why?
|
Transcription Factors | 1 | 2004 | 5362 | 0.010 |
Why?
|